Patent US5732707A successfully refreshed from Google Patents.
US5732707A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of ultrasonically quantitating myocardial perfusion using as intravenously injected tracer
Assignee: Molecular Biosystems Inc
•
Filing: 1996-06-05
•
Granted: 1998-03-31
•
Expires: 2016-06-05
Abstract
Abstract Myocardial perfusion is assessed quantitatively by an ultrasonic echocardiographic procedure in which: the myocardium is ultrasonically imaged; an ultrasonic contrast agent consisting of a suspension of pressure-stable, water-insoluble gas-containing microspheres sized to pass through the pulmonary capillaries is injected intravenously; imaging is continued through the first transit of the microspheres through the myocardium; the videodensity versus time relationship is determined from the images; and blood flow through the myocardium is calculated from that relationship.
Inventors
- 👤 Kenneth J. Widder
- 👤 Harold B. Levene
- 👤 Gary L. Bales
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 07:56
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/22; A61K49/222; A61K49/223; A61B; A61B8/00; A61B8/06; A61B8/48; A61B8/481
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
137 words
A method of quantitatively measuring blood flow in the myocardium of a patient comprising: (a) initiating ultrasonic imaging of the myocardium; (b) while said imaging is continued, intravenously injecting an effective dosage of a suspension of biocompatible tracer microspheres containing an insoluble gas into the patient, wherein: (i) the microspheres have a mean diameter that permits them to pass through the pulmonary capillaries of the patient and (ii) said suspension is capable of maintaining 25% of the initial optical density at 600 nm after being subjected to a pressure of 5 psi for 30 seconds; (c) continuing said imaging during the first transit of the microspheres through the myocardium; (d) determining a videodensity versus time relationship from the images obtained in steps (a) through (c); and (e) calculating the blood flow in the myocardium from said relationship.
Claim 2
Independent Claim
137 words
A method of quantitatively measuring blood flow in the myocardium of a patient comprising: (a) initiating ultrasonic imaging of the myocardium; (b) while said imaging is continued, intravenously injecting an effective dosage of a suspension of biocompatible tracer microspheres containing an insoluble gas into the patient, wherein: (i) the microspheres have a mean diameter that permits them to pass through the pulmonary capillaries of the patient and (ii) said suspension is capable of maintaining 25% of the initial optical density at 600 nm after being subjected to a pressure of 5 psi for 30 seconds; (c) continuing said imaging during the first transit of the microspheres through the myocardium; (d) determining a videodensity versus time relationship from the images obtained in steps (a) through (c); and (e) calculating the blood flow in the myocardium from said relationship.
Claim 3
Dependent Claim
22 words
The method of claim 1 wherein the microspheres have a mean diameter in the range of about 2 to about 10 micrometers.
Claim 4
Dependent Claim
22 words
The method of claim 1 wherein the microspheres have a mean diameter in the range of about 4 to about 7 micrometers.
Claim 5
Dependent Claim
42 words
The method of claim 3 wherein said suspension contains a microsphere concentration of 5×10 7 to 5×10 9 per mL and the dosage is in the range of 12 to 40 μL of said suspension per kg body weight of the patient.
Claim 6
Dependent Claim
17 words
The method of claim 1 wherein the microspheres are human serum albumin microspheres containing a perfluoroalkane gas.
Claim 7
Dependent Claim
10 words
The method of claim 5 wherein the gas is perfluoropropane.
Claim 8
Dependent Claim
56 words
The method of claim 5 wherein the microspheres have a mean diameter in the range of about to 7 micrometers, the microsphere concentration in the suspension is 5×10 8 to 1×10 9 per mL and the dosage is in the range of 20 to 32 μL of suspension per kg of body weight of the patient.
Claim 9
Dependent Claim
22 words
The method of claim 1 wherein the microspheres have a mean diameter in the range of about 2 to about 5 micrometers.
Claim 10
Dependent Claim
22 words
The method of claim 1 wherein the imaging is a three dimensional imaging procedure performed by any conventional three dimensional imaging device.
Claim 11
Dependent Claim
57 words
The method of claim 6 wherein the microspheres have a mean diameter in the range of about 2 to 5 micrometers, the microsphere concentration in the suspension is 5×10 8 to 1×10 9 per mL and the dosage is in the range of 20 to 32 μL of suspension per kg of body weight of the patient.
References Cited (Backward Citations)
WO1980002365A1
Cited
US4316391A
Cited
US5040537A
Cited
WO1989006978A1
Cited
US4957656A
Cited
WO1991009629A1
Cited
WO1991012823A1
Cited
US5137928A
Cited
US5190982A
Cited
EP0458745B1
Cited
US5315997A
Cited
US5135000A
Cited
US5149543A
Cited
WO1992017213A1
Cited
WO1992018164A1
Cited
WO1993002712A1
Cited
US5413774A
Cited
EP0554213B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-30 | 2001-09-29 | 2002-03-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-30 | 2005-09-29 | 2006-03-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-30 | 2009-09-29 | 2010-03-31 | $7700.00 | Window Closed / Lapsed |